CRISPR Therapeutics AG
CRSP
$56.25
-$0.43-0.76%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -81.10% | -81.18% | -86.13% | -89.95% | 19.31% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -81.10% | -81.18% | -86.13% | -89.95% | 19.31% |
| Cost of Revenue | -0.46% | -27.73% | -26.28% | -30.31% | -23.23% |
| Gross Profit | -85.25% | -10.54% | -45.39% | -120.92% | 44.33% |
| SG&A Expenses | 2.71% | 2.15% | 3.57% | -4.18% | -11.77% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.50% | -11.25% | -10.22% | -15.14% | -9.84% |
| Operating Income | -43.85% | -28.63% | -58.86% | -109.66% | 21.54% |
| Income Before Tax | -104.92% | -76.26% | -77.66% | -140.62% | 34.38% |
| Income Tax Expenses | 19.23% | 49.74% | 73.30% | 24.20% | 145.74% |
| Earnings from Continuing Operations | -103.80% | -75.99% | -77.61% | -138.43% | 32.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -103.80% | -75.99% | -77.61% | -138.43% | 32.23% |
| EBIT | -43.85% | -28.63% | -58.86% | -109.66% | 21.54% |
| EBITDA | -46.76% | -30.45% | -63.16% | -120.67% | 22.29% |
| EPS Basic | -99.22% | -69.20% | -67.30% | -123.71% | 37.49% |
| Normalized Basic EPS | -60.35% | -34.61% | -67.36% | -125.77% | 39.50% |
| EPS Diluted | -97.13% | -67.70% | -65.52% | -121.12% | 36.73% |
| Normalized Diluted EPS | -59.04% | -33.65% | -65.95% | -123.12% | 39.00% |
| Average Basic Shares Outstanding | 5.47% | 5.49% | 6.74% | 6.48% | 5.11% |
| Average Diluted Shares Outstanding | 4.95% | 4.96% | 6.20% | 5.94% | 5.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |